The next major milestone for the MR-linac project will be the first scans of a human body which will be undertaken on a volunteer.
Dr Ananya Choudhury, clinical lead for MR-linac at The Christie, said: “The MR-linac is a flagship research project for The Christie using state-of-the-art experimental technology to deliver more precise, more personalised, more effective and kinder radiotherapy to our patients. It lets us see tumours very clearly and treat them at the same time with pinpoint accuracy.”
Ad Statistics
Times Displayed: 90433
Times Visited: 5810 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
Fundraisers at The Christie charity are contributing £1m towards the overall £5.3m cost of the MR-linac. The first patient treatment, as part of a trial, will be available at The Christie once regulatory approval has been given. This is anticipated during 2018.
The Christie is working with six other leading international cancer centres in North America and Europe as part of the Elekta MR-linac consortium. The MRI technology partner for Elekta is the global electronics giant Philips.
Bringing MR-linac to The Christie, along with proton beam therapy from 2018 onwards, will ensure that the hospital remains at the forefront of leading edge radiotherapy treatment and research. The Christie NHS Foundation Trust has been ranked ‘Outstanding’ by the health regulator the Care Quality Commission (CQC) which referred to it as ‘exceptional’ and ‘a leader in its field’. It not only commended the Trust for its effectiveness and care, but highlighted its work in shaping the future of cancer care and noted the reach and influence of its clinical research projects. The CQC also rated The Christie the best specialist trust in the country, and one of the top three trusts overall in England.
Back to HCB News
